retatrutide obesity triple hormone receptor agonist Original Article: Triple–Hormone-Receptor for — A Phase 2 Trial https://t.co/jNL1GNnHPT #ADA23 Weight loss with retatrutide as

The best thing you can do is have a conversation with a healthcare provider

Retatrutide is developed by Eli Lilly with expected approval in late 2026 or early 2027

Semaglutide activates the GLP-1 receptor, while tirzepatide activates both GIP and GLP-1 receptors

A large retrospective meta-analysis of prospectively adjudicated cardiovascular events has been recently published, including data from 40 double-blind, randomised-controlled phase III and IV studies encompassing about 17,500 patients (mean age 57 years) receiving vildagliptin 50 mg once and twice daily, or comparators [116]

Research shows that once-weekly injections improve adherence by 11% compared to daily options